Trillium Therapeutics Receives Prestigious National Award
Marketwire - Fri Jun 13, 9:01AM CDT
Trillium Therapeutics Inc. ("TTI"
Stem Cell Therapeutics Changes Its Name to Trillium Therapeutics Inc.
Marketwire - Thu Jun 05, 1:37AM CDT
Stem Cell Therapeutics Corp. ("SCT"
Stem Cell Therapeutics Announces Results of Annual Shareholders Meeting
Marketwire - Wed May 28, 7:46AM CDT
Stem Cell Therapeutics Corp. ("SCT"
Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report 2014
M2 - Mon May 19, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwbmb9/circulating_tumor) has announced the addition of the "Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Click the link below to view the full, extended table of contents. I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. CIRCULATING TUMOR CELLS (CTCS) GLOBAL MARKET OVERVIEW - Real-Time Liquid Biopsy' Scores Over Surgical Biopsy - Challenges in CTC Diagnostics - Need for CTC Enrichment and Popular Methods 2. MARKET TRENDS AND DRIVERS - CTCs for Personalized Cancer Treatment - Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis - CTC Microdevices Hog the Limelight 3. CANCER STEM CELLS GLOBAL MARKET OVERVIEW - CSC-Focused Innovations in Cancer Therapeutics - Select Pathways or Molecular Targets for CSC Candidates - Pipeline Analysis of Select Cancer Stem Cells Therapeutics ( 2014) 4. CTC AND CSC RESEARCH FINDINGS & BREAKTHROUGHS - Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity - NBiomics Makes its Contribution to CTC Diagnosis - Researchers at University of Michigan Develop Revolutionary Capture CTCs Method 5. MEDICAL DIAGNOSTICS MARKET A CONCEPTUAL OVERVIEW - Molecular Diagnostics for Lymphoid Malignancies - Market Trends & Issues - Global Molecular Diagnostics on a High Growth Curve - Automation Driving Global Market - Molecular Diagnostics: Marking Convergence of Numerous Technologies 6. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS - Filtration (iSET) - Density Gradient - Immuno-magnetic Cell Enrichment - Advantages of Different CTC Enrichment Procedures - AdnaTest 7. CANCER STEM CELLS (CSCS) BIOLOGY, ISOLATION, CSC SURFACE MARKERS, AND SIGNALING PATHWAYS - Differences between Normal Stem Cells and Cancer Stem Cells - Hierarchical versus Stochastic Models of Tumour Cell Heterogeneity - Isolation of Cancer Stem Cells - Characteristics of Cancer Stem Cells - Resistance to Chemotherapy - Resistance to Radiation - Invasion or Metastatic Activity 8. PRODUCT LAUNCHES AND INTRODUCTIONS - EU Authorisation for ANGLE's Parsortix Cancer Diagnostic Device - ANGLE Launches Parsortix Device into the Research Market - Promab Introduces New Range of Cancer Stem Cells Solutions - Clearbridge BioMedics Unveils ClearCell? FX Cancer Cell Enrichment System - Fluxion Introduces New IsoFlux System CTC Technology - Cynvenio Launches LiquidBiopsy Lab Service - Biocept Launches OncoCEE-BR - ApoCell to Launch ApoStream 9. RECENT INDUSTRY ACTIVITY - Stem Cell Therapeutics and University of York Ink Option Agreement - Veridex Undergoes Name Change to Janssen Diagnostics - Janssen Diagnostics and Arno Therapeutics Ink Collaboration Agreement - Veridex Enters into Agreement with LabCorp - Stemline Therapeutics Obtains Orphan Drug Designation for SL-401 10. FOCUS ON SELECT MAJOR PLAYERS IN CTC DIAGNOSTICS - Adnagen GmbH (Germany) - ApoCell, Inc (US) - Biocep LTD (Israel) - Biocept, Inc. (US) - Biofluidica Microtechnologies LLC (US) - Celltrafix Inc. (US) - Clearbridge Biomedics (Singapore) - Creatv Microtech, Inc (US) - Cynvenio Biosystems, Inc. (US) - Ikonisys, Inc. (US) - IVDiagnostics, Inc. (US) - Janssen Diagnostics LLC (US) - Epic Biosciences Inc (US) - RARECELLS SAS (Italy) - SCREENCELL (France) - Stemcell Technologies, Inc. (Canada) 11. SELECT MARKET PARTICIPANTS IN THE CANCER STEM CELLS (CSCS) SPACE - Alchemia Limited (Australia) - Amgen Inc. (US) - Exelixis, Inc. (US) - Formula Pharmaceuticals (US) - GlaxoSmithKline Plc. (UK) - Geron Corp. (US) - Infinity Pharmaceuticals (US) - Kalobios Pharmaceuticals Inc. (US) - Novartis AG (Switzerland) - OncoMed Pharmaceuticals, Inc. (US) - Pfizer, Inc. (US) - Roche Diagnostics (Switzerland) - Verastem, Inc. (US) 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 66 (including Divisions/Subsidiaries 67) - The United States (46) - Canada (3) - Japan (2) - Europe (9) - France (3) - Germany (2) - The United Kingdom (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (4) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/vw...ting_tumor
Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Stem Cell Therapeutics Announces Resignation of Director
Marketwire - Mon Jan 27, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, announces that effective today, Mr. David Allan has resigned from its board of directors.
Stem Cell Therapeutics Provides Corporate Update
Marketwire - Mon Jan 13, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today provided the following six-month corporate update:
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.
Stem Cell Therapeutics Completes $33 Million Private Placement
Marketwire - Fri Dec 13, 3:50PM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell- related therapeutics, is pleased to announce that it has raised gross proceeds of $33 million through a private placement of units. The financing proceeds will be used to advance the Company's CD47 cancer stem cell program through IND-enabling studies, manufacturing and phase 1 clinical trials.
Stem Cell Therapeutics Adopts Shareholder Rights Plan
Marketwire - Tue Sep 17, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan"